Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...